Boutique Service. Global Reach.
Exclusively focused on PDX models for oncology drug development, the Champions TumorGraft® platform is a powerful solution for any preclinical and simulated clinical research initiatives. From leading multi-national pharmaceutical organizations to emerging biotechs, our TumorBank of over 800 patient-derived xenograft (PDX) models has proven to be a valuable resource for organizations attempting to identify the ideal patient population for their drug.
A Patient-Centric Approach
A clear differentiator here at Champions is our patient-centric approach. As the only PDX provider that directly works with both patients and drug developers, we are wholly committed to ensuring the most clinically relevant, predictive PDX models available.
Our models are consistent with the desired patient profile for oncology clinical trials – heavily pretreated, metastatic, advanced-stage disease with relevant molecular and pathological characteristics. Because we source our models through established relationships, we are well-equipped to provide accurate and well-documented diagnoses and medical histories.